Jorg T Hartmann
Overview
Explore the profile of Jorg T Hartmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
3702
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S, et al.
Lancet
. 2019 Apr;
393(10184):1948-1957.
PMID: 30982686
Background: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and...
2.
Lyros O, Thomaidis T, Muller M, Sivanathan V, Grimminger P, Lang H, et al.
Oncol Res Treat
. 2018 Feb;
41(3):122-128.
PMID: 29485415
Background: Despite the announcement of the 8th edition of TNM classification, the 7th edition (2010) is still being used for prognostic assessment in gastric cancer patients. A proposed new staging...
3.
Al-Batran S, Homann N, Pauligk C, Illerhaus G, Martens U, Stoehlmacher J, et al.
JAMA Oncol
. 2017 Apr;
3(9):1237-1244.
PMID: 28448662
Importance: Surgical resection has a potential benefit for patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. Objective: To evaluate outcome in patients with limited metastatic disease who receive...
4.
Joensuu H, Wardelmann E, Sihto H, Eriksson M, Hall K, Reichardt A, et al.
JAMA Oncol
. 2017 Mar;
3(5):602-609.
PMID: 28334365
Importance: Little is known about whether the duration of adjuvant imatinib influences the prognostic significance of KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor α (PDGFRA) mutations....
5.
Schmitt T, Mayer-Steinacker R, Mayer F, Grunwald V, Schutte J, Hartmann J, et al.
Eur J Cancer
. 2016 Jul;
64:74-82.
PMID: 27367154
Introduction: New treatment options for patients with metastatic Soft Tissue Sarcoma are urgently needed. Preclinical studies suggested activity of vorinostat, a histone deacetylase inhibitor. Methods: A multi-centre, open-label, non-randomised phase...
6.
Casali P, Cesne A, Velasco A, Kotasek D, Rutkowski P, Hohenberger P, et al.
J Clin Oncol
. 2015 Nov;
33(36):4276-83.
PMID: 26573069
Purpose: In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery patients with localized, high- or intermediate-risk GI stromal tumor (GIST). Patients...
7.
Joensuu H, Eriksson M, Hall K, Reichardt A, Hartmann J, Pink D, et al.
J Clin Oncol
. 2015 Nov;
34(3):244-50.
PMID: 26527782
Purpose: Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft...
8.
Joensuu H, Eriksson M, Hall K, Hartmann J, Pink D, Schutte J, et al.
Cancer
. 2014 Apr;
120(15):2325-33.
PMID: 24737415
Background: Little is known about the factors that predict for gastrointestinal stromal tumor (GIST) recurrence in patients treated with adjuvant imatinib. Methods: Risk factors for GIST recurrence were identified, and...
9.
Judson I, Verweij J, Gelderblom H, Hartmann J, Schoffski P, Blay J, et al.
Lancet Oncol
. 2014 Mar;
15(4):415-23.
PMID: 24618336
Background: Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role. Whether...
10.
Al-Batran S, Pauligk C, Homann N, Hartmann J, Moehler M, Probst S, et al.
Eur J Cancer
. 2012 Oct;
49(4):835-42.
PMID: 23063354
Background: We evaluated the feasibility and tolerability of triple- versus double-drug chemotherapy in elderly patients with oesophagogastric cancer. Methods: Patients aged 65 years or older with locally advanced or metastatic...